Alcohol abuse is a leading cause of morbidity and mortality worldwide and recent data indicate that alcoholic liver disease affects over 10 million Americans. In addition to the classically appreciated impact of alcohol use on the liver, injury to other organs, such as the intestine, skeletal muscle, kidney, adipose tissue and the neural system contribute to morbidity and mortality associated with chronic alcohol abuse. Understanding both the common and tissue-specific mechanisms by which ethanol impairs cellular and organ function will lead to the development of rationally designed therapeutic interventions to both prevent and reverse tissue damage and disease resulting from chronic alcohol consumption. The overall goal of the Northeast Ohio Alcohol Center (NOAC) is to identify specific molecular targets of ethanol-induced damage, as well as understand the complex adaptive and maladaptive responses of cells and systems to that damage, This information will enable us to 1) target therapeutic interventions that will either slow and/or reverse the progression of alcohol-induced organ injury and 2) development of specific assays that can assess the efficacy of novel therapeutic strategies in relevant clinical populations. NOAC brings together an outstanding team of interdisciplinary investigators and is supported by an Administrative Core, an Animal Models and Cell Isolation Core, a Clinical Core and a Pilot Projects Core, as well as outstanding state-of-the-art facilities at 4 premier research institution in Northeast Ohio: the Cleveland Clinic, Case Western Reserve University/University Hospitals, Northeast Ohio Medical University and Nationwide Children's Hospital at the Ohio State University. Four Research Components (RC) are proposed: RC1 (Brown) investigates the interaction between ethanol and gut microbial metabolites and the generation of ethanol-induced tissue injury, RC2 (You) interrogates the impact of ethanol metabolism in liver on lipin-1 and SIRT1, key regulators of hepatocyte lipid homeostasis; RC3 (Dasarathy) is designed to understand the impact of chronic ethanol on skeletal muscle wasting, a critical co-morbid feature of alcoholic liver disease and RC4 (Nagy) investigates the interactions between inflammation and hepatocellular death via necroptosis/apoptosis. The long-term goal of NOAC is to translate novel findings on the specific mechanisms by which ethanol disrupts cellular and organ function into effective treatment strategies for patients with alcoholic tissue injury. Our outstanding investigative team and excellent Core facilities will continue to work collaboratively to address key mechanistic and translational problems of alcohol- induced tissue injury, providing unique strengths for translating novel findings the molecular and cellular mechanisms of ethanol action and disease progression into the development of treatment strategies.
Alcohol abuse is a leading cause of morbidity and mortality worldwide and recent data indicate that alcoholic liver disease affects over 10 million Americans. The overall goal of the Northeast Ohio Alcohol Center (NOAC) is to identify specific molecular targets of ethanol-induced damage, as well as understand the complex adaptive and maladaptive responses of cells and systems to that damage. This information will enable us to target therapeutic interventions that will either slow and/or reverse the progression of disease in patients suffering from injury due to excessive alcohol consumption.
|You, Min (2018) Obesity and Binge Drinking: Two Hits Driving Liver Fibrosis Progression? Cell Mol Gastroenterol Hepatol 5:424-425|
|You, Min; Zhou, Zhou; Daniels, Michael et al. (2018) Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury. Gene Expr 18:103-113|
|Roberts, Adam B; Gu, Xiaodong; Buffa, Jennifer A et al. (2018) Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med 24:1407-1417|
|Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231|
|Dasarathy, Srinivasan; Hatzoglou, Maria (2018) Hyperammonemia and proteostasis in cirrhosis. Curr Opin Clin Nutr Metab Care 21:30-36|
|Lindenmeyer, Christina C; McCullough, Arthur J (2018) The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis 22:11-21|
|Manterola, Andrea; Bernal-Chico, Ana; Cipriani, Raffaela et al. (2018) Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. Biochem Pharmacol 157:189-201|
|McCullough, Rebecca L; McMullen, Megan R; Poulsen, Kyle L et al. (2018) Anaphylatoxin Receptors C3aR and C5aR1 Are Important Factors That Influence the Impact of Ethanol on the Adipose Secretome. Front Immunol 9:2133|
|Chen, Li; Chen, Ruju; Kemper, Sherri et al. (2018) Pathways of production and delivery of hepatocyte exosomes. J Cell Commun Signal 12:343-357|
|McCullough, Rebecca L; McMullen, Megan R; Sheehan, Megan M et al. (2018) Complement Factor D protects mice from ethanol-induced inflammation and liver injury. Am J Physiol Gastrointest Liver Physiol 315:G66-G79|
Showing the most recent 10 out of 42 publications